Vanchieri C. Preparing for Thalidomide's Comeback. Ann Intern Med. 1997;127:951-952. doi: 10.7326/0003-4819-127-10-199711150-00023
Download citation file:
Published: Ann Intern Med. 1997;127(10):951-952.
Thalidomide is on the verge of being introduced-with great care-into the U.S. marketplace. The news provokes polarized reactions: disbelief that such a potent teratogen could be made available after the lessons of almost 40 years ago, and impatience for a drug that can lead to exceptional improvements in some rare debilitating immune diseases.
In early September, an advisory committee to the U.S. Food and Drug Administration (FDA) recommended that the FDA approve marketing of thalidomide for erythema nodosum leprosum, an inflammatory manifestation of leprosy that results in painful cutaneous lesions on the arms, legs, and face. The committee also strongly recommended limiting distribution of thalidomide, with stringent safety measures put in place to avoid birth defects and other side effects.
Learn more about subscription options.
Register Now for a free account.
Emergency Medicine, Infectious Disease, Mycobacterial Infections, Prevention/Screening.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only